656 related articles for article (PubMed ID: 18559986)
21. Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.
Karaplis AC; Bai X; Falet JP; Macica CM
Endocrinology; 2012 Dec; 153(12):5906-17. PubMed ID: 23038738
[TBL] [Abstract][Full Text] [Related]
22. Osteocyte-specific deletion of Fgfr1 suppresses FGF23.
Xiao Z; Huang J; Cao L; Liang Y; Han X; Quarles LD
PLoS One; 2014; 9(8):e104154. PubMed ID: 25089825
[TBL] [Abstract][Full Text] [Related]
23. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease.
Wolf M; White KE
Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):411-9. PubMed ID: 24867675
[TBL] [Abstract][Full Text] [Related]
24. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
Quarles LD
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
[TBL] [Abstract][Full Text] [Related]
25. Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.
Ichikawa S; Gray AK; Padgett LR; Allen MR; Clinkenbeard EL; Sarpa NM; White KE; Econs MJ
Endocrinology; 2014 Oct; 155(10):3891-8. PubMed ID: 25051439
[TBL] [Abstract][Full Text] [Related]
26. Mutational analysis of PHEX, FGF23 and DMP1 in a cohort of patients with hypophosphatemic rickets.
Ruppe MD; Brosnan PG; Au KS; Tran PX; Dominguez BW; Northrup H
Clin Endocrinol (Oxf); 2011 Mar; 74(3):312-8. PubMed ID: 21050253
[TBL] [Abstract][Full Text] [Related]
27. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
Kinoshita Y; Fukumoto S
Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
[TBL] [Abstract][Full Text] [Related]
28. Molecular analysis of DMP1 mutants causing autosomal recessive hypophosphatemic rickets.
Farrow EG; Davis SI; Ward LM; Summers LJ; Bubbear JS; Keen R; Stamp TC; Baker LR; Bonewald LF; White KE
Bone; 2009 Feb; 44(2):287-94. PubMed ID: 19007919
[TBL] [Abstract][Full Text] [Related]
29. Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice.
Murali SK; Andrukhova O; Clinkenbeard EL; White KE; Erben RG
PLoS Biol; 2016 Apr; 14(4):e1002427. PubMed ID: 27035636
[TBL] [Abstract][Full Text] [Related]
30. DMP1 Ablation in the Rabbit Results in Mineralization Defects and Abnormalities in Haversian Canal/Osteon Microarchitecture.
Liu T; Wang J; Xie X; Wang K; Sui T; Liu D; Lai L; Zhao H; Li Z; Feng JQ
J Bone Miner Res; 2019 Jun; 34(6):1115-1128. PubMed ID: 30827034
[TBL] [Abstract][Full Text] [Related]
31. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Athonvarangkul D; Insogna KL
Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
[TBL] [Abstract][Full Text] [Related]
32. Soluble Klotho causes hypomineralization in Klotho-deficient mice.
Minamizaki T; Konishi Y; Sakurai K; Yoshioka H; Aubin JE; Kozai K; Yoshiko Y
J Endocrinol; 2018 Jun; 237(3):285-300. PubMed ID: 29632215
[TBL] [Abstract][Full Text] [Related]
33. Sclerostin antibody (Scl-Ab) improves osteomalacia phenotype in dentin matrix protein 1(Dmp1) knockout mice with little impact on serum levels of phosphorus and FGF23.
Ren Y; Han X; Jing Y; Yuan B; Ke H; Liu M; Feng JQ
Matrix Biol; 2016; 52-54():151-161. PubMed ID: 26721590
[TBL] [Abstract][Full Text] [Related]
34. [Regulation and disorders of calcium and phosphate metabolism].
Michigami T
Clin Calcium; 2014 Feb; 24(2):169-75. PubMed ID: 24473349
[TBL] [Abstract][Full Text] [Related]
35. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.
Imel EA; DiMeglio LA; Hui SL; Carpenter TO; Econs MJ
J Clin Endocrinol Metab; 2010 Apr; 95(4):1846-50. PubMed ID: 20157195
[TBL] [Abstract][Full Text] [Related]
36. Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism.
Gattineni J; Baum M
Pediatr Nephrol; 2010 Apr; 25(4):591-601. PubMed ID: 19669798
[TBL] [Abstract][Full Text] [Related]
37. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.
Liu S; Rowe PS; Vierthaler L; Zhou J; Quarles LD
J Endocrinol; 2007 Jan; 192(1):261-7. PubMed ID: 17210763
[TBL] [Abstract][Full Text] [Related]
38. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.
Farrow EG; Yu X; Summers LJ; Davis SI; Fleet JC; Allen MR; Robling AG; Stayrook KR; Jideonwo V; Magers MJ; Garringer HJ; Vidal R; Chan RJ; Goodwin CB; Hui SL; Peacock M; White KE
Proc Natl Acad Sci U S A; 2011 Nov; 108(46):E1146-55. PubMed ID: 22006328
[TBL] [Abstract][Full Text] [Related]
39. FGF23 and syndromes of abnormal renal phosphate handling.
Bergwitz C; Jüppner H
Adv Exp Med Biol; 2012; 728():41-64. PubMed ID: 22396161
[TBL] [Abstract][Full Text] [Related]
40. ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate.
David V; Martin A; Hedge AM; Drezner MK; Rowe PS
Am J Physiol Renal Physiol; 2011 Mar; 300(3):F783-91. PubMed ID: 21177780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]